Anxo Pharmaceutical Co., Ltd.

As of June 30, 2026, Anxo Pharmaceutical Co., Ltd. carries a market capitalization of 927.45M, placing it among publicly traded companies globally. Its enterprise value stands at 1.45B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Anxo Pharmaceutical Co., Ltd. has 56.04M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Anxo Pharmaceutical Co., Ltd. maintains a current ratio of 1.45, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Anxo Pharmaceutical Co., Ltd.'s stock has declined approximately 24.50% over the past 52 weeks. The 50-day moving average sits at 18.07, while the 200-day moving average is 18.40.

As of June 30, 2026, Anxo Pharmaceutical Co., Ltd. holds 334.82M in cash and equivalents against 741.47M in total debt, resulting in a net debt position of 403.18M. Total book value stands at 986.52M, with working capital of 260.81M providing operational flexibility.

Anxo Pharmaceutical Co., Ltd.'s most recent stock split took place on July 11, 2023 with a 190:197 split ratio.